Asthma and Allergy News and Research

Help Others See Beyond Asthma and Allergies During National Asthma and Allergy Awareness Month

Each May since 1984, the Asthma and Allergy Foundation of America (AAFA) has declared May to be National Asthma and Allergy Awareness Month. This month is dedicated to teaching others about asthma and allergies to create more awareness and understanding. We also want to help people see beyond asthma and allergies. This year, we aim to do just that through our themes, “More Than Asthma” and “More Than Food Allergies.”

FDA Approves Dupixent® for Moderate-to-Severe Atopic Dermatitis in Adolescents

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

GSK, Maker of ADVAIR DISKUS®, Announces Authorized Generic

The Asthma and Allergy Foundation of America is sharing this press release from GlaxoSmithKline (GSK) to bring you the latest research news quickly. [PRESS RELEASE] GSK Announces Availability of Authorized Generic ADVAIR DISKUS® (fluticasone propionate/salmeterol inhalation powder) GSK announced today plans to make available an authorized generic (AG) of ADVAIR DISKUS (fluticasone propionate/salmeterol inhalation powder) in all three approved strengths. The authorized generic will be...

FDA Approves First Generic ADVAIR DISKUS® for Asthma Treatment

The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).

GSK to Offer Generic Version of Ventolin HFA Albuterol Inhaler

The Asthma and Allergy Foundation of America is sharing this press release from GlaxoSmithKline to bring you the latest research news quickly. [PRESS RELEASE] GSK announces availability of Authorized Generic Albuterol Sulfate Inhaler for treatment or prevention of bronchospasm Effective, January 15, 2019, GSK announced the availability of an authorized generic (AG) of Ventolin HFA (albuterol sulfate) inhalation aerosol. The AG will be manufactured by GSK and distributed by Prasco LLC. The...

Teva Announces FDA Approval of ProAir® Digihaler™

Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved ProAir ® Digihaler™ (albuterol sulfate 117 mcg) inhalation powder, the first and only digital inhaler with built-in sensors which connects to a companion mobile application and provides inhaler use information to people with asthma and COPD. Learn more.

×
×
×
×